Chemical structure:

IUPAC name:

(S)-1-[N-(3-Hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile

CAS number:

274901-16-5

Therapy area:

Anti-diabetic

References:

IH

Status:

Commercial scale

Mechanism of action

Vildagliptin causes extended enzyme inhibition by forming a covalent bond with the DPP-4 catalytic site. This increases intact GLP-1 levels both after meals and throughout a fast. Vildagliptin has been found to act in a glucose-dependent way to increase insulin secretion and decrease glucagon secretion. Vildagliptin increases the counterregulatory glucagon response in comparison to baseline at hypoglycemic levels. Vildagliptin also enhances insulin sensitivity, as evaluated by a number of techniques, and decreases the generation of hepatic glucose, mostly through altering islet hormone secretion.

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.